KMT2A and leukemia: For the CRISPR screen, we used an MLL-AF9-driven murine leukemia model we generated previously in a dsRed-transgenic background, allowing convenient tracking of leukemia cells upon serial transplantation in recipient mice (Miller et al., 2013).